Dr. Dario Dornbierer

I’m passionate about the intricate interplay between the brain and the mind and how chemical substances can dramatically change the way we perceive the outer and inner world.

About Dario

Dario Dornbierer is a pharmaceutical scientist (ETH Zurich), Swiss Federal pharmacist and clinical psychopharmacologist who specialises in drug development in mental health.

After a residency year in a Swiss pharmacy, Dario conducted a PhD in the field of clinical psychopharmacology at the Psychiatric University Hospital in Zurich, where he investigated the antidepressant potential of several drug candidates, applying state-of-the-art neuroscientific methods (EEG, MRI, etc.). With a special focus on sleep pharmacology, he investigated the ability of several compounds to promote deep sleep and improve overall sleeping and waking functions.

In his role as CSO and Board Member at B・SYNC ON parent company, Galventa, Dario is responsible for all aspects related to pharmaceutical technology, clinical sciences and innovation.

Says Dario, “I’m passionate about the intricate interplay between the brain and the mind and how chemical substances can dramatically change the way we perceive the outer and inner world. As a pharmacist, I find it exciting to apply cutting-edge pharmaceutical technologies to the fields of psychopharmacology to improve the safety, tolerability and efficacy of products, thus addressing the urgent unmet clinical need in mental health.”

Dario was granted two entrepreneurial postdoc fellowships to advance his innovative work towards marketable products. He has co-founded two biotech startups focused on mental health and sleep.

Dario is passionate about spending time with his wife and two kids, gardening and playing various instruments.


A novel bedtime pulsatile-release caffeine formula ameliorates sleep inertia symptoms immediately upon awakening

Molecular and functional imaging studies of hallucinogenic drug action in animals and humans

Towards Extending the Detection Window of Gamma-Hydroxybutyric Acid

Disorders due to use of hallucinogens

Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring

Neurophysiological signature of gamma-hydroxybutyrate augmented sleep in healthy volunteers may reflect biomimetic sleep enhancement

Nocturnal gamma-hydroxybutyrate reduces cortisol awakening response and morning tryptophan catabolites in healthy volunteers

Elevated morning glutamate levels in the anterior cingulate cortex after a nighttime dose of gamma-hydroxybutyrate in humans

Prohedonic properties of gamma-hydroxybutyrate are associated with changes in limbic resting-state functional connectivity

Identification of new urinary gamma-hydroxybutyric acid (GHB) markers applying untargeted metabolomics analysis following placebo-controlled administration to humans

Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone

Gamma-hydroxybutyrate increases brain resting-state functional connectivity of the salience network and dorsal nexus in humans

Gamma-hydroxybutyrate increases resting-state limbic perfusion and body and emotion awareness in humans

Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects

Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers

Neural initialization of audiovisual integration in prereaders at varying risk for developmental dyslexia


Meet the team of scientists and innovators, that are working every day to help you improve your sleep and waking up.